- Home
- CDIO vs RNAZ Comparison
CDIO vs RNAZ Comparison
Compare CDIO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- RNAZ
- Stock Information
- Founded
- CDIO 2017
- RNAZ 2016
- Country
- CDIO United States
- RNAZ United States
- Employees
- CDIO N/A
- RNAZ N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- RNAZ Health Care
- Exchange
- CDIO Nasdaq
- RNAZ Nasdaq
- Market Cap
- CDIO 6.4M
- RNAZ 6.1M
- IPO Year
- CDIO N/A
- RNAZ 2021
- Fundamental
- Price
- CDIO $4.39
- RNAZ $11.74
- Analyst Decision
- CDIO Buy
- RNAZ Strong Buy
- Analyst Count
- CDIO 1
- RNAZ 1
- Target Price
- CDIO $60.00
- RNAZ $280.00
- AVG Volume (30 Days)
- CDIO 41.0K
- RNAZ 239.7K
- Earning Date
- CDIO 08-11-2025
- RNAZ 08-13-2025
- Dividend Yield
- CDIO N/A
- RNAZ N/A
- EPS Growth
- CDIO N/A
- RNAZ N/A
- EPS
- CDIO N/A
- RNAZ N/A
- Revenue
- CDIO $19,902.00
- RNAZ N/A
- Revenue This Year
- CDIO $1,434.82
- RNAZ N/A
- Revenue Next Year
- CDIO $4,661.91
- RNAZ N/A
- P/E Ratio
- CDIO N/A
- RNAZ N/A
- Revenue Growth
- CDIO N/A
- RNAZ N/A
- 52 Week Low
- CDIO $3.22
- RNAZ $6.15
- 52 Week High
- CDIO $53.10
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- CDIO 50.34
- RNAZ 67.96
- Support Level
- CDIO $4.11
- RNAZ $9.02
- Resistance Level
- CDIO $4.73
- RNAZ $17.24
- Average True Range (ATR)
- CDIO 0.33
- RNAZ 1.28
- MACD
- CDIO 0.10
- RNAZ 0.31
- Stochastic Oscillator
- CDIO 65.03
- RNAZ 40.21
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.